Encephalopathy News and Research RSS Feed - Encephalopathy News and Research

Lupin introduces first Brand product Zaxine in Canada

Lupin introduces first Brand product Zaxine in Canada

Pharma Major Lupin Limited announced today that its Canadian subsidiary, Lupin Pharma Canada Limited (collectively Lupin) has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc. [More]
Study reveals new target for research into liver disease

Study reveals new target for research into liver disease

In a recent study, Virginia Commonwealth University School of Medicine researchers predicted which cirrhosis patients would suffer inflammations and require hospitalization by analyzing their saliva, revealing a new target for research into a disease that accounts for more than 30,000 deaths in the United States each year. [More]
Inflammation plays causal role in neurologic changes associated with Lyme disease

Inflammation plays causal role in neurologic changes associated with Lyme disease

About 15% of patients with Lyme disease develop peripheral and central nervous system involvement, often accompanied by debilitating and painful symptoms. New research indicates that inflammation plays a causal role in the array of neurologic changes associated with Lyme disease, according to a study published in The American Journal of Pathology. [More]
Robert B. Kiningham receives Founders' Award at 2015 AMSSM Annual Meeting

Robert B. Kiningham receives Founders' Award at 2015 AMSSM Annual Meeting

Robert B. Kiningham, MD, was awarded the Founders' Award at the 24th American Medical Society for Sports Medicine Annual Meeting in Hollywood, Fla. The award is bestowed when AMSSM leadership determines that a member exemplifies the best that a sports medicine physician can be and do. [More]
Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

Medunik Canada, a Canadian pharmaceutical company specialized in rare diseases, is pleased to announce that PHEBURANE (a tasteless oral formulation of sodium phenylbutyrate), is now available for distribution in Canada. PHEBURANE is the first drug to be approved in Canada for the chronic management of urea cycle disorders (UCD) after receiving market authorisation on January 27th, 2015. [More]
FDA approves Quadracel vaccine to protect young children from life-threatening diseases

FDA approves Quadracel vaccine to protect young children from life-threatening diseases

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. [More]
European scientists identify gene linked with certain types of early-onset epilepsy

European scientists identify gene linked with certain types of early-onset epilepsy

Certain types of early-onset epilepsy are caused by previously unknown mutations of a potassium channel gene, KCNA2. The mutations disrupt the electrical balance in the brain in two ways. In some patients, the flow of potassium is greatly reduced; while in others, it is raised enormously. Both states can lead to hard-to-treat epileptic seizures. Mental and motor development can come to a stop, or even to regress. [More]
Study identifies small loop in human prion protein that resists chronic wasting disease

Study identifies small loop in human prion protein that resists chronic wasting disease

Chronic wasting disease (CWD) — an infectious disease caused by prions — affects North American elk and deer, but has not been observed in humans. Using a mouse model that expresses an altered form of the normal human prion protein, researchers at University of California, San Diego School of Medicine have determined why the human proteins aren't corrupted when exposed to the elk prions. [More]
Virginia Tech biochemists identify potential drug target against sleeping sickness

Virginia Tech biochemists identify potential drug target against sleeping sickness

Virginia Tech biochemists are trying to deliver a stern wake-up call to the parasite that causes sleeping sickness. [More]
TSRI scientists discover novel mechanism involved in Alzheimer's, Parkinson's and ALS

TSRI scientists discover novel mechanism involved in Alzheimer's, Parkinson's and ALS

Scientists from the Florida campus of The Scripps Research Institute have for the first time discovered a killing mechanism that could underpin a range of the most intractable neurodegenerative diseases such as Alzheimer's, Parkinson's and ALS. [More]
'Mad Cow' discovery points to possible neuron killing mechanism behind alzheimer’s and parkinson’s diseases

'Mad Cow' discovery points to possible neuron killing mechanism behind alzheimer’s and parkinson’s diseases

The new study, published recently in the journal Brain, revealed the mechanism of toxicity of a misfolded form of the protein that underlies prion diseases, such as bovine spongiform encephalopathy (“mad cow disease”) and its human equivalent, Creutzfeldt-Jakob disease. [More]
Use of STAN in addition to usual monitoring does not improve perinatal outcomes

Use of STAN in addition to usual monitoring does not improve perinatal outcomes

In a study to be presented on Feb. 5 in an oral plenary session at 8 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in San Diego, researchers will report that use of the ST segment (STAN) as an adjunct to conventional intrapartum electronic fetal heart rate monitoring did not improve perinatal outcomes or decrease operative deliveries in hospitals in the United States. [More]
Groundbreaking study reveals potential dangers of ice hockey for young athletes

Groundbreaking study reveals potential dangers of ice hockey for young athletes

James Hudziak, M.D., has two children who love ice hockey. His son skates for his college team and one of his daughters plays in high school. [More]
Kaleo, CHMI partner to reduce prescription drug-related deaths

Kaleo, CHMI partner to reduce prescription drug-related deaths

Kaleo, a privately-held pharmaceutical company, today announced a national strategic partnership with the Clinton Health Matters Initiative, an initiative of the Clinton Foundation, that will help support its goal of cutting prescription drug-related deaths in half, saving approximately 10,000 lives over five years. [More]
Scrapie pathogens can convert human prion protein to a pathological state

Scrapie pathogens can convert human prion protein to a pathological state

INRA scientists have shown for the first time that the pathogens responsible for scrapie in small ruminants (prions) have the potential to convert the human prion protein from a healthy state to a pathological state. In mice models reproducing the human species barrier, this prion induces a disease similar to Creutzfeldt-Jakob disease. [More]
Deeper cooling does not reduce NICU death among newborns with hypoxic ischemic encephalopathy

Deeper cooling does not reduce NICU death among newborns with hypoxic ischemic encephalopathy

Among full-term newborns with moderate or severe hypoxic ischemic encephalopathy (damage to cells in the central nervous system from inadequate oxygen), receiving deeper or longer duration cooling did not reduce risk of neonatal intensive care unit death, compared to usual care, according to a study in the December 24/31 issue of JAMA. [More]
First successful vaccination of deer against chronic wasting disease

First successful vaccination of deer against chronic wasting disease

Researchers at NYU Langone Medical Center and elsewhere say that a vaccination they have developed to fight a brain-based, wasting syndrome among deer and other animals may hold promise on two additional fronts: Protecting U.S. livestock from contracting the disease, and preventing similar brain infections in humans. [More]
Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). [More]
Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm. [More]
Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Advertisement
Advertisement